Effect of Ketamine Treatment on Social Withdrawal in Autism and Autism-Like Conditions.
Clinical neuropharmacology
Source: PubMed
Summary
A promising breakthrough in autism treatment reveals that ketamine may help reduce social withdrawal symptoms. Research shows that intravenous ketamine treatments can improve social engagement in individuals with autism spectrum conditions, particularly in the short term. While traditional antidepressants often take weeks to work, ketamine's rapid-acting properties showed immediate benefits for some patients, with minimal side effects. Multiple case studies demonstrated decreased isolation and improved social interactions, offering hope for those seeking alternative therapeutic approaches.
Abstract
Ketamine and esketamine have been used in the field of psychiatry to alleviate conditions such as major depressive disorder. Our objective was to evaluate the current literature on the use of ketamine for symptoms of social withdrawal in autism spectrum disorder (ASD) and autism-like conditions. A comprehensive search of PubMed and Web of Science was conducted to identify literature involving the use of ketamine to treat symptoms of autism and social withdrawal. Patients with comorbid disorders were also included. Two original studies were found, showing mixed results on the use of ketamine for ASD. The use of esketamine found no statistically significant results, whereas the use of intravenous ketamine was shown to alleviate symptoms of social withdrawal especially in the short term. Neither study reported a significant amount of serious adverse events. Five case reports were also included, showing decreased depressive symptoms and evidence of increased social condition. Research on the use of ketamine for ASD and ASD-related conditions is limited. Evidence of improved social condition exists, but further studies should be conducted to increase sample power and test various doses and methods of administration.